Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06153667 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)

Study acronym: BETTER-UAE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jun 2026 → Jun 2027
See other at-risk trials from Merit Medical Systems, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 2026 to Jun 2027
    • Study completion pushed from Dec 2026 to Jun 2027
    • Eligibility criteria expanded, about 6 words
    • Site details revised at 1 of 4 sites
  2. Site details revised at 1 of 4 sitesv6
  3. Primary completion date: Apr 2025 to Jun 2026
    • Study sites: 1 to 4
    • Study completion date: Oct 2025 to Dec 2026
    v5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 2024 to Aug 22, 2024
    v4
  5. Study title expanded, about 1 wordv3
  6. Start date: Apr 2024 to Jun 2024v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.
Trial Details
NCT Number NCT06153667
Lead Sponsor Merit Medical Systems, Inc.
Conditions
(from sponsor)		 Uterine Fibroid
Related terms Leiomyoma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov